You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國醫藥(600056.SH):子公司收到硫辛酸注射液的藥品註冊證書
格隆匯 10-13 18:12

格隆匯10月13日丨中國醫藥(600056.SH)公佈,近日,公司下屬全資子公司天方藥業有限公司(“天方有限”)收到國家藥品監督管理局核准簽發的兩份硫辛酸注射液(“該藥品”,規格:12ml:0.3g、24ml:0.6g)《藥品註冊證書》。

截至公吿披露日,天方有限在該藥品研發項目累計投入約為1003.91萬元人民幣(未經審計)。

該藥品適用於糖尿病周圍神經病變引起的感覺異常。該藥品為Hameln Pharmaceuticals GmbH(德國史達德大藥廠)研發,並於1999年在德國上市,規格為12ml:300mg,商品名為Alpha(奧力寶®);目前,硫辛酸注射液在中國已批准進口上市。

根據國家藥監局網站數據查詢顯示,截至公吿披露日,除天方有限外,目前國內硫辛酸注射液共有15個生產廠家、23個批准文號,主要包括山東新時代藥業有限公司、亞寶藥業集團股份有限公司、成都倍特藥業股份有限公司等。天方有限為首家獲批24ml:0.6g規格的硫辛酸注射液國內生產廠家。

根據PDB數據庫樣本醫院用藥銷售統計顯示,2020年該藥品樣本醫院銷售總金額約為2.85億元人民幣。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account